My read from the last line of the announcement is that the pivotal trial is in ARDS
Sure - they regurgitated a whole heap of previously announced ad hoc analysis from the Covid trial - but my read is a pivotal study on ARDS with perhaps a separate over & under 65 cohorts.
Happy to be corrected
Ann: Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients, page-24
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.08 | $5.380M | 4.893M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 69437 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 19999 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |